Hypercalcemic crisis due to primary hyperparathyroidism treated by zoledronate in a patient with end-stage renal disease

DOI Web Site 14 References

Bibliographic Information

Other Title
  • 原発性副甲状腺機能亢進症による高カルシウムクリーゼに対しゾレドロネートが奏効した末期腎不全患者の１例
  • 症例報告 原発性副甲状腺機能亢進症による高カルシウムクリーゼに対しゾレドロネートが奏効した末期腎不全患者の1例
  • ショウレイ ホウコク ゲンパツセイ フクコウジョウセン キノウ コウシンショウ ニ ヨル コウカルシウム クリーゼ ニ タイシ ゾレドロネート ガ ソウコウ シタ マッキ ジンフゼン カンジャ ノ 1レイ

Search this article

Description

Hypercalcemic crisis is a serious and potentially life-threatening complication of markedly increased serum calcium concentrations most commonly due to primary hyperparathyroidism. We report a case of an 80-year-old man with diabetes mellitus and chronic renal failure, who presented to the emergency department with somnolence, dysarthria and severe hypercalcemia (16.3mg/dL). Despite intensive treatment including elcatonin, alendronate, and intermittent hemodialysis with low calcium dialysate, serum calcium still reached high levels between hemodialysis treatments. The patient was then treated with 4mg of intravenous zoledronate. This treatment greatly reduced the serum calcium level and improved clinical symptoms without major adverse effects. The patient was diagnosed as having primary hyperparathyroidism and was treated by parathyroidectomy. Administration of zoledronate seems to be an effective modality for hypercalcemic crisis in patients with end-stage renal disease.

Journal

References(14)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top